StreetAlpha.app
Home › Stocks › SER

Serina Therapeutics, Inc. (SER)

$1.36
▼ −2.50%
LAST CLOSE · NOV 17

Serina Therapeutics develops drug candidates using its POZ polymer delivery technology, with a lead treatment for Parkinson's disease. It last closed at $1.36 on Nov 17, down 2.50% on the day.

AI Auto Pilots
Is SER in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$125K
+7.8% vs a year ago
Net income
−$24.5M
−19596.8% margin
EPS (diluted)
−$1.63
Free cash flow
−$22.8M
−18268.8% margin
Valuation
Market cap
$36.3M
26.6M shares
P/E
–
No P/E while losing money
Price to sales
290.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$19.4M
At Sep 30
Shareholder equity
$13.9M
Shares outstanding
26.6M
At Nov 10
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $144K$144KFY2021FY2022: $34K$34KFY2022FY2023: $3.2M$3.2MFY2023FY2024: $56K$56KFY2024FY2025: $130K$130KFY2025

From SER's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated SER in the past 90 days, not enough for a consensus
Average 12-month target
$8.00
▲ 486.1% upside

Based on 1 analyst who set a price target on SER in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $1.36.

Low $8.00Avg $8.00High $8.00
Blue marker: last close $1.36
Highest target$8.00
Average target$8.00
Lowest target$8.00
Latest rating changes
BTIGReiterated
Sep 10Buy$8
BTIGInitiated
Jul 1Buy$8
DateFirmActionRatingPrice target
Sep 10BTIGReiteratedBuy$8
Jul 1BTIGInitiatedBuy$8
Loading…

Technical Analysis

SER · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 18% below its 20 day and 38% below its 50 day average. It is 47% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot at $1.34, and the nearest resistance the Pivot R1 at $1.42.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 14.9%/day
Key levels
$4.2652 week high+213.2%
$2.11100 day average+55.1%
$2.01200 day average+47.8%
$1.8950 day average+39.0%
$1.6120 day average+18.4%
$1.55Swing high (Nov 12)+14.0%
$1.42Pivot R1+4.4%
$1.36Last close
$1.34Pivot−1.5%
$1.29Swing low (Nov 6)−5.1%
$1.28Pivot S1−5.9%
$1.2252 week low−10.3%
Indicators
RSI (14)33.54Weak, oversold below 30Neutral
MACD-0.15Below its signal lineBearish
Stochastic9.0Near the bottom of its rangeOversold
ADX (14)25.5Trending down
Williams %R-91.9Oversold below −80, overbought above −20Oversold
CCI (20)-113.3Oversold below −100, overbought above 100Oversold
Rate of change−23.7%Change over 10 sessionsBearish
ATR (14)$0.20Typical daily range, 14.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SER

What happened before

See how SER did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SER usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SER has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SER in the last 90 days.

Loading…

See today’s whale options flow across the market →

SER Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●9 buying vs 8 selling
  • ▲Held by funds +4.1 pts
  • ▲Funds holding +1
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2827+3.7%
In funds' top 1000–
Held by funds9.4%5.3%+4.1 pts
New / increased4 / 54 / 6−10.0%
Reduced / sold out5 / 34 / 3+14.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SER institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SER is in one of them and how their past SER trades turned out.

SER in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SER in an article yet. Here's the latest on the wider market.

About Serina Therapeutics

Serina Therapeutics is a biotechnology company based in Huntsville, Alabama. It develops drug candidates that use its proprietary POZ polymer technology, which is designed to control how a drug is released and how long it stays active in the body. Its lead candidate, SER 252, is being developed to treat Parkinson's disease and is in clinical development. The company also plans to work with pharmaceutical partners on other uses of its platform, including RNA-based therapies and antibody drug conjugates.

Headquarters
Huntsville, AL